Zhi Liu Phones & Addresses
-
Mooresville, NC
-
Apex, NC
-
High Point, NC
-
10 Weslyn Park Dr, Savannah, GA 31419
-
1845 Dunmore Ln, Clemmons, NC 27012
-
6831 Hanesbrook Cir, Clemmons, NC 27012 (336) 778-9021
-
Greensboro, NC
-
Winston Salem, NC
-
Raleigh, NC
-
Hardeeville, SC
Education
School / High School:
Southern Methodist University, Dedman School of Law
Ranks
Licence:
New York - Currently registered
Date:
2002
Business Records
Name / Title
Company / Classification
Phones & Addresses
Director
TX LIU'S INC
Publications
Isbn (Books And Publications)
China's Urban Transport Development Strategy: Proceedings of a Symposium in Beijing, November 8-10, 1995
View page
Author
Zhi Liu
ISBN #
0821338412
Us Patents
Stable Solutions Of Orlistat For Pharmaceutical Dosage Forms
View pageUS Patent:
8309107, Nov 13, 2012
Filed:
Oct 6, 2009
Appl. No.:
12/574215
Inventors:
Zhi Liu - Jamestown NC, US
Dana S. Toops - Parkland FL, US
Aqeel A. Fatmi - Greensboro NC, US
Dana S. Toops - Parkland FL, US
Aqeel A. Fatmi - Greensboro NC, US
Assignee:
Banner Pharmacaps, Inc. - High Point NC
International Classification:
A61K 9/00
A61K 9/48
A61K 31/365
A61K 31/355
A61K 31/375
A61K 9/48
A61K 31/365
A61K 31/355
A61K 31/375
US Classification:
424400, 424408, 424451, 514458, 514449, 514474
Abstract:
Liquid orlistat-containing fill materials suitable for encapsulating in hard or soft capsules are described herein. The fill material contains orlistat dissolved in one or more medium chain triglycerides or medium chain partial triglycerides, one or more citrate esters, and combinations thereof. The fill material can also contain one or more pharmaceutically acceptable excipients. In one embodiment, the fill material is substantially free of surfactants. The fill material can be encapsulated in hard or soft, gelatin or non-gelatin capsules. The capsules may be coated to modify release of orlistat from the capsule. Alternatively, the fill material can be encapsulated in an enteric capsule, wherein the enteric polymer is a component of the capsule shell, rather than a coating over the capsule shell. The fill materials are stable at elevated temperatures over an extended period of time and allow for high loadings of orlistat (e. g. , 20% w/w or higher).
Progesterone Solutions For Increased Bioavailability
View pageUS Patent:
20100255085, Oct 7, 2010
Filed:
Apr 1, 2010
Appl. No.:
12/752629
Inventors:
Zhi Liu - Jamestown NC, US
Saujanya L. Gosangari - Greensboro NC, US
Dana S. Toops - Parkland FL, US
Aqeel Fatmi - Greensboro NC, US
Saujanya L. Gosangari - Greensboro NC, US
Dana S. Toops - Parkland FL, US
Aqeel Fatmi - Greensboro NC, US
International Classification:
A61K 9/48
A61K 31/57
A61P 5/34
A61K 31/57
A61P 5/34
US Classification:
424456, 424451, 514177, 424463
Abstract:
Fill materials for hydrophobic drugs, such as progesterone, and methods of making and using thereof are described herein. The fill material contains the hydrophobic drug dissolved in one or more fatty acids. The concentration of the hydrophobic drug is typically from about 7% to about 50% by weight of the fill material. The concentration of the one or more fatty acids is from about 60% to about 95% by weight of the carrier. The formulation also contains an organic acid and one or both of one or more pharmaceutically acceptable alcohols and one or more pharmaceutically acceptable mono-, di-, or triesters of medium or long chain fatty acids. The fill material can be encapsulated in a hard or soft capsule. The formulations described herein have a higher dissolution rate and faster onset of dissolution compared to micronized progesterone suspended in an oil and thus should have increased bioavailability in vivo.